<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05014724</url>
  </required_header>
  <id_info>
    <org_study_id>CIDP07</org_study_id>
    <nct_id>NCT05014724</nct_id>
  </id_info>
  <brief_title>CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)</brief_title>
  <official_title>CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma SRL</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <brief_summary>
    <textblock>
      This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients&#xD;
      who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit&#xD;
      from treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rozanolixizumab</intervention_name>
    <description>Rozanolixizumab is dosed weekly at 10 mg/kg. Patients should continue to receive the dose they were receiving in the CIDP04 (NCT04051944) trial.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient who has taken part in the CIDP04 (NCT04051944) study&#xD;
&#xD;
          -  Patient who derives continued benefit from treatment&#xD;
&#xD;
          -  All required safety information has been reported as per local laws/regulations,&#xD;
             reported to Bionical, as appropriate, and documented in the patient's medical records&#xD;
&#xD;
          -  Patient is not pregnant&#xD;
&#xD;
        Exclusion Criteria:&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>001 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>UCB Cares</last_name>
    <phone>0018445992273</phone>
    <email>UCBCares@ucb.com</email>
  </overall_contact>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic inflammatory demyelinating polyradiculoneuropathy</keyword>
  <keyword>CIDP</keyword>
  <keyword>UCB7665</keyword>
  <keyword>rozanolixizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyneuropathies</mesh_term>
    <mesh_term>Polyradiculoneuropathy, Chronic Inflammatory Demyelinating</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rozanolixizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

